Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients.

Related Articles Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. 2019 Mar 14;25(10):1266-1277 Authors: Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K Abstract BACKGROUND: Asymptomatic children with Crohn’s disease (CD) require ongoing monitoring to ensure early recognition of a disease exacerbation. AIM: In a cohort of pediatric CD patients, we aimed to assess the utility of serial fecal calprotectin measurements to detect intestinal inflammatory activity and predict disease relapse. METHODS: In this prospective longitudinal cohort study, children with CD…

Read More

Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.

Related Articles Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol. 2019 Mar 07;25(9):1142-1157 Authors: Damião AOMC, de Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC Abstract BACKGROUND: Despite the advent of biological drugs, conventional therapy continues to be used in moderate to severe inflammatory bowel disease (MS-IBD). This study hypothesized that as a standard of treatment and the primary alternative to biologics, conventional therapy should present robust effectiveness results in IBD outcomes. AIM: To investigate the effectiveness of conventional therapy…

Read More

Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use.

Related Articles Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol. 2019 Feb 28;25(8):989-1001 Authors: Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ Abstract BACKGROUND: Ulcerative colitis (UC) is an uncommon inflammatory bowel disease (IBD). However, its incidence has recently increased in South Korea. Moreover, UC diagnoses are frequently delayed, and the relationship between diagnostic delay and UC prognosis has not been extensively studied in South Korean patients. AIM: To identify meaningful diagnostic delay…

Read More

Crohn’s-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case report.

Related Articles Crohn’s-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case report. World J Gastroenterol. 2019 Feb 28;25(8):1031-1036 Authors: Girot P, Le Berre C, De Maissin A, Freyssinet M, Trang-Poisson C, Bourreille A Abstract BACKGROUND: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, platelet storage pool deficiency and systemic complications associated with ceroid deposition in the reticuloendothelial system. HPS types 1 and 4 are associated with Crohn’s disease (CD)-like gastrointestinal disorders, such as granulomatous enterocolitis or perianal disease. Cases of colitis can be particularly…

Read More

Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.

Related Articles Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019 Feb 14;25(6):659-671 Authors: Fung BM, Lindor KD, Tabibian JH Abstract Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra- and/or extrahepatic biliary ducts. While its features and disease course can be variable, most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly, PSC is associated…

Read More

Fatigue in children and adolescents with inflammatory bowel disease.

Fatigue in children and adolescents with inflammatory bowel disease. World J Gastroenterol. 2019 Feb 07;25(5):632-643 Authors: Van de Vijver E, Van Gils A, Beckers L, Van Driessche Y, Moes ND, van Rheenen PF Abstract AIM: To identify factors other than active disease and anemia that contribute to fatigue in pediatric inflammatory bowel disease (IBD). METHODS: We performed an electronic search in Medline and EMBASE from their inception to May 2017 using the search term “fatigue” or the related keywords “physical impairment” and “inflammatory bowel disease” with the filter “child” (age…

Read More

Differentiating Crohn’s disease from intestinal tuberculosis.

Related Articles Differentiating Crohn’s disease from intestinal tuberculosis. World J Gastroenterol. 2019 Jan 28;25(4):418-432 Authors: Kedia S, Das P, Madhusudhan KS, Dattagupta S, Sharma R, Sahni P, Makharia G, Ahuja V Abstract Differentiating Crohn’s disease (CD) and intestinal tuberculosis (ITB) has remained a dilemma for most of the clinicians in the developing world, which are endemic for ITB, and where the disease burden of inflammatory bowel disease is on the rise. Although, there are certain clinical (diarrhea/hematochezia/perianal disease common in CD; fever/night sweats common in ITB), endoscopic (longitudinal/aphthous ulcers common…

Read More

Novel oral-targeted therapies for mucosal healing in ulcerative colitis.

Related Articles Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol. 2018 Dec 21;24(47):5322-5330 Authors: Antonelli E, Villanacci V, Bassotti G Abstract Ulcerative colitis (UC), a chronic, relapsing, remitting disease of the colon and rectum, is characterized by inflammatory ulceration of the mucosa. Current UC therapy relies on controlling acute episodes and preventing relapse. To predict modifications in the natural course of UC, mucosal healing (MH) has emerged as a major treatment goal. Endoscopic evaluation is considered the gold standard for assessing MH, which can be achieved…

Read More

Five years of fecal microbiota transplantation – an update of the Israeli experience.

Related Articles Five years of fecal microbiota transplantation – an update of the Israeli experience. World J Gastroenterol. 2018 Dec 21;24(47):5403-5414 Authors: Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N Abstract AIM: To evaluate and describe the efficacy of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in a national Israeli cohort. METHODS: All patients who received FMT for recurrent (recurrence within 8 wk of the previous treatment) or refractory CDI from 2013 through 2017 in all…

Read More

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.

Related Articles Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018 Dec 14;24(46):5288-5296 Authors: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á Abstract BACKGROUND: Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the…

Read More
<< Go Back